2026-04-13T06:38:36Zhttps://recercat.cat/oai/request
oai:recercat.cat:2445/1761442025-12-05T13:19:17Zcom_2072_1057col_2072_478798col_2072_478916col_2072_478917
RECERCAT author Solanich, Xavier author Fernández Huerta, Miguel author Basaez, Celeste author Antolí, Arnau author Rocamora Blanch, Gemma author Corbella, Xavier author Santín Cerezales, Miguel author Alcaide Fernández de Vega, Fernando 2021-04-09T13:28:05Z2021-04-09T13:28:05Z2021-02-262021-04-09T13:28:05Z Performance of the QuantiFERON-TB Gold Plus (QFT-Plus) assay could be affected by conditions of immune dysregulation. Little is known about the reliability of QTF-Plus in COVID-19 patients. Our aim was to determine the prevalence and the factors related to an indeterminate QFT-Plus test in COVID-19 hospitalized patients, and to analyze its relationship with in-hospital mortality. A retrospective analysis of all hospitalized COVID-19 patients on whom a QTF-Plus assay was performed in a tertiary care public hospital during the first epidemic wave in Spain (March-April 2020). Out of a total of 96 patients included, 34 (35.4%) had an indeterminate result, in all cases due to a lack of response in the mitogen control. Factors related to COVID-19 severity, such as higher lactate dehydrogenase (LDH) (odds ratio [OR] 1.005 [95% confidence interval [CI] 1.002-1.008]) and previous administration of corticosteroids (OR 4.477 [95% CI 1.397-14.345]), were independent predictors for indeterminate QFT-Plus assay. Furthermore, indeterminate results were more frequent among COVID-19 patients who died during hospitalization (29.1% vs. 64.7%; p = 0.005). We conclude that QFT-Plus assay yielded an unexpected, high prevalence of indeterminate results in severe COVID-19 patients. Factors related to worse COVID-19 outcome, such as LDH, as well as corticosteroid use before the QFT-Plus assay, seem to be predictors for an indeterminate result. The role of an indeterminate QFT-Plus result in predicting COVID-19 severity and mortality should be evaluated. cc-by (c) Solanich, Xavier et al., 2021 http://creativecommons.org/licenses/by/3.0/es info:eu-repo/semantics/openAccess COVID-19 Mortalitat COVID-19 Mortality Clinical significance of indeterminate QuantiFERON-TB Gold Plus assay results in hospitalized COVID-19 patients with severe hyperinflammatory syndrome info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion